EPTMF (Epitomee Medical) ROE %: -35.55% (As of Dec. 2025)


EPTMF Epitomee Medical Ltd EPTMF
29 GF Score
Price $0.99
! 3 Warning Signs
View Full Analysis

What is Epitomee Medical ROE %?

Epitomee Medical EPTMF 29 ROE % is -35.55% as of Dec. 2025. GuruFocus rates EPTMF with a GF Score™ of 29/100. The stock has 3 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Epitomee Medical ranks worse than 77.47% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Epitomee Medical's annualized net income for the quarter that ended in Dec. 2025 was $-10.07 Mil. Epitomee Medical's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was $28.34 Mil. Therefore, Epitomee Medical's annualized ROE % for the quarter that ended in Dec. 2025 was -35.55%.

The historical rank and industry rank for Epitomee Medical's ROE % or its related term are showing as below:

EPTMF' s ROE % Range Over the Past 10 Years
Min: -81.12   Med: -33.19   Max: -4.26
Current: -28.51

During the past 8 years, Epitomee Medical's highest ROE % was -4.26%. The lowest was -81.12%. And the median was -33.19%.

EPTMF's ROE % is ranked worse than
77.47% of 799 companies
in the Medical Devices & Instruments industry
Industry Median: 2.42 vs EPTMF: -28.51

Epitomee Medical  (OTCPK:EPTMF) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=-10.074/28.339
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-10.074 / 0.426)*(0.426 / 35.0735)*(35.0735 / 28.339)
=Net Margin %*Asset Turnover*Equity Multiplier
=-2364.79 %*0.0121*1.2376
=ROA %*Equity Multiplier
=-28.61 %*1.2376
=-35.55 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=-10.074/28.339
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-10.074 / -10.074) * (-10.074 / -9.996) * (-9.996 / 0.426) * (0.426 / 35.0735) * (35.0735 / 28.339)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.0078 * -2346.48 % * 0.0121 * 1.2376
=-35.55 %

Note: The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Epitomee Medical ROE % Related Terms


Epitomee Medical ROE % Historical Data

* Premium members only.

The historical data trend for Epitomee Medical's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Epitomee Medical ROE % Chart

Epitomee Medical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE %
Get a 7-Day Free Trial -40.22 -33.19 -15.31 -4.26 -28.75

Epitomee Medical Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.84 -33.23 24.49 -22.11 -35.55

EPTMF vs ABT, SYK, MDT: ROE % Comparison

For the Medical Devices subindustry, Epitomee Medical's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Epitomee Medical ROE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Epitomee Medical's ROE % distribution charts can be found below:

* The bar in red indicates where Epitomee Medical's ROE % falls into.


EPTMF
29GF Score
Epitomee Medical Ltd EPTMF
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Epitomee Medical ROE % Calculation

Epitomee Medical's annualized ROE % for the fiscal year that ended in Dec. 2025 is calculated as

ROE %=Net Income (A: Dec. 2025 )/( (Total Stockholders Equity (A: Dec. 2024 )+Total Stockholders Equity (A: Dec. 2025 ))/ count )
=-8.612/( (33.952+25.961)/ 2 )
=-8.612/29.9565
=-28.75 %

Epitomee Medical's annualized ROE % for the quarter that ended in Dec. 2025 is calculated as

ROE %=Net Income (Q: Dec. 2025 )/( (Total Stockholders Equity (Q: Jun. 2025 )+Total Stockholders Equity (Q: Dec. 2025 ))/ count )
=-10.074/( (30.717+25.961)/ 2 )
=-10.074/28.339
=-35.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2025) net income data. ROE % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of -35.55% mean?
Epitomee Medical (EPTMF) has a ROE % of -35.55% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Epitomee Medical and its competitors. According to the industry distribution chart, Epitomee Medical ranks #619 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 77.5%.
Is Epitomee Medical's ROE % too high?
Epitomee Medical's current ROE % is -35.55%. Based on the distribution chart, Epitomee Medical ranks #619 out of 799 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Epitomee Medical has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Epitomee Medical's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Epitomee Medical ranks #619 out of 799 companies for ROE %. This places Epitomee Medical in the lower half of its industry. The industry median ROE % is 2.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Epitomee Medical and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Epitomee Medical's current ROE % is -35.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epitomee Medical stock overvalued right now?
Epitomee Medical (EPTMF) has a current ROE % of -35.55%. The current ROE % is -35.55%. Epitomee Medical's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Epitomee Medical (EPTMF), the current ROE % is -35.55% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Epitomee Medical Business Description

Other Exchanges EPIT:Israel
Address Tarshish 19, Caesarea, ISR, 3088900
Epitomee Medical Ltd is engaged in developing and commercializing ingestible therapeutic devices.
29GF Score

Get the complete analysis for EPTMF

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.99
Price